Logo

MOLN

Molecular Partners AG

MOLN

Molecular Partners AG • NASDAQ
$4.12 ▲ 0.53% (+0.02)
Market Cap $154.13 M
52w High $5.99
52w Low $3.36
Dividend Yield 0%
P/E -2.05
Volume 468
Outstanding Shares 37.40M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $12.045M ▲ $-11.836M ▲ 0% $-0.32 ▲ $-11.306M ▲
Q2-2025 $0 $6.611M ▲ $-20.398M ▼ 0% $-0.55 ▼ $-19.841M ▼
Q1-2025 $0 $4.221M ▼ $-16.771M ▼ 0% $-0.45 ▼ $-16.215M ▼
Q4-2024 $0 ▼ $5.345M ▲ $-11.232M ▲ 0% ▲ $-0.33 ▲ $-10.654M ▲
Q3-2024 $681K $4.406M $-16.404M -2.409K% $-0.49 $-15.804M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $104.521M ▼ $112.15M ▼ $16.621M ▼ $95.529M ▼
Q2-2025 $114.486M ▼ $124.252M ▼ $17.591M ▲ $106.661M ▼
Q1-2025 $130.907M ▼ $141.097M ▼ $12.904M ▼ $128.193M ▼
Q4-2024 $149.439M ▲ $158.528M ▲ $16.891M ▲ $141.637M ▲
Q3-2024 $143.618M $154.211M $15.433M $138.778M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.835M ▲ $-9.926M ▲ $10.664M ▼ $-304K ▼ $384K ▼ $-9.957M ▲
Q2-2025 $-20.396M ▼ $-13.1M ▲ $14.97M ▼ $-243K ▲ $604K ▼ $-13.196M ▲
Q1-2025 $-16.771M ▼ $-17.08M ▼ $34.963M ▲ $-302K ▼ $17.497M ▲ $-17.528M ▼
Q4-2024 $-11.232M ▲ $-13.195M ▲ $-4.494M ▼ $15.301M ▲ $-1.878M ▼ $-13.332M ▲
Q3-2024 $-16.404M $-13.282M $14.22M $-301K $66K $-13.54M

Five-Year Company Overview

Income Statement

Income Statement Molecular Partners looks like a classic clinical‑stage biotech: very little recurring revenue and a pattern of operating losses most years. The one standout year of profit appears linked to a large, likely one‑time partnership or milestone payment rather than ongoing product sales. Since then, the company has slipped back into modest but steady losses as it continues to fund research and clinical trials. Overall, the income statement tells a story of a platform company still in the investment phase, dependent on occasional deal income and not yet on commercial products.

Balance Sheet

Balance Sheet The balance sheet is relatively clean and conservative. The company holds a meaningful cash position compared with its total size and carries essentially no financial debt, which lowers financial risk. Equity makes up most of the funding base, consistent with an early‑stage biotech financed mainly by shareholders and partners. Assets have eased down from prior peaks, reflecting the gradual use of cash to fund development, but the structure still points to a company with some financial cushion and a simple, low‑leverage profile.

Cash Flow

Cash Flow Cash flows show a pattern of money flowing out to support research and clinical work, with only one recent year of strong positive inflow that likely came from a major collaboration payment. Operating and free cash flow are usually negative, but not extreme, and capital spending on equipment and facilities is minimal. This means most cash burn is tied directly to scientific and clinical activity rather than heavy infrastructure, giving management some flexibility to slow or redirect spending if needed. The stated goal of extending the cash runway into the second half of the decade will be important to watch against future trial costs and partnership income.

Competitive Edge

Competitive Edge The company’s edge rests on its proprietary DARPin platform, which offers a differentiated way to design protein drugs compared with traditional antibodies. This is reinforced by a broad patent estate, long accumulated know‑how, and clinical experience in several disease areas. Strategic alliances with large pharma players validate the technology and help with funding and expertise. However, the broader oncology and protein‑therapy field is intensely crowded, with many well‑funded competitors, so sustaining a real edge will depend on turning this platform advantage into clearly better clinical outcomes and partnerships over time.

Innovation and R&D

Innovation and R&D Innovation is the core of the Molecular Partners story. The DARPin platform allows for multi‑specific, customizable protein therapies, and the company is pushing into cutting‑edge areas like radio‑conjugated DARPins and “switch” immune activators. The pipeline is diversified within oncology and related areas, with several candidates at or approaching early‑stage human trials. Partnerships with players like Novartis and Orano Med suggest external confidence in the technology. The main risk is typical for biotech: the science is promising but still needs to be proven in larger, later‑stage studies, and timelines can be long and uncertain.

Summary

Molecular Partners is a platform‑driven biotech with a distinctive technology, a clean balance sheet, and an R&D‑heavy financial profile. The income statement and cash flows reflect a company still firmly in development mode, relying on partnerships and financing rather than product revenue. Its technology, patent protection, and strategic collaborations provide a credible competitive foundation, especially in oncology and radiopharmaceuticals, but success ultimately depends on future clinical data and deal flow. Overall, this is a high‑innovation, higher‑risk profile typical of early‑stage biotech: strong scientific promise, but financial outcomes will hinge on how the pipeline and partnerships evolve over the next several years.

NEWS

November 12, 2025 · 1:00 AM UTC

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

Read more

November 3, 2025 · 1:00 AM UTC

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

Read more

October 30, 2025 · 4:00 PM UTC

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Read more